PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics

PLUS THERAPEUTICS, Inc. (PSTV): $1.81

0.05 (-2.43%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add PSTV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#61 of 350

in industry

PSTV Price/Volume Stats

Current price $1.81 52-week high $5.10
Prev. close $1.85 52-week low $0.97
Day low $1.76 Volume 41,300
Day high $1.85 Avg. volume 32,492
50-day MA $1.93 Dividend yield N/A
200-day MA $1.96 Market Cap 7.72M

PSTV Stock Price Chart Interactive Chart >

PSTV POWR Grades

  • Sentiment is the dimension where PSTV ranks best; there it ranks ahead of 82.2% of US stocks.
  • The strongest trend for PSTV is in Quality, which has been heading up over the past 100 days.
  • PSTV ranks lowest in Stability; there it ranks in the 1st percentile.

PSTV Stock Summary

  • PSTV has a higher market value than just 4.27% of US stocks; more precisely, its current market capitalization is $8,186,007.
  • Revenue growth over the past 12 months for PLUS THERAPEUTICS INC comes in at 5,038.36%, a number that bests 99.83% of the US stocks we're tracking.
  • In terms of volatility of its share price, PSTV is more volatile than 93.55% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PLUS THERAPEUTICS INC are SCYX, ARQT, TGTX, MNTS, and GENE.
  • Visit PSTV's SEC page to see the company's official filings. To visit the company's web site, go to www.plustherapeutics.com.

PSTV Valuation Summary

  • In comparison to the median Healthcare stock, PSTV's EV/EBIT ratio is 100.68% lower, now standing at -0.1.
  • Over the past 243 months, PSTV's price/sales ratio has gone down 1.8.

Below are key valuation metrics over time for PSTV.

Stock Date P/S P/B P/E EV/EBIT
PSTV 2023-12-29 2.1 3.0 -0.5 -0.1
PSTV 2023-12-28 2.1 2.9 -0.5 -0.1
PSTV 2023-12-27 2.2 3.2 -0.5 -0.1
PSTV 2023-12-26 2.3 3.3 -0.6 -0.1
PSTV 2023-12-22 2.3 3.3 -0.6 -0.1
PSTV 2023-12-21 2.3 3.2 -0.6 -0.1

PSTV Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at 78.56%.
  • Its 3 year revenue growth rate is now at -100%.
  • Its 2 year revenue growth rate is now at -100%.
PSTV's revenue has moved down $6,925,000 over the prior 33 months.

The table below shows PSTV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.073 -13.362 -18.772
2022-06-30 0 -11.391 -17.277
2022-03-31 0 -11.15 -14.795
2021-12-31 0 -10.28 -13.399
2021-09-30 0 -10.88 -12.831
2021-06-30 0 -10.928 -10.835

PSTV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PSTV has a Quality Grade of D, ranking ahead of 14.57% of graded US stocks.
  • PSTV's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
  • CSII, XENT, and CRY are the stocks whose asset turnover ratios are most correlated with PSTV.

The table below shows PSTV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.000 NA -6.744
2021-06-30 0.000 NA -4.780
2021-03-31 0.013 1 -4.834
2020-12-31 0.021 1 -4.324
2020-09-30 0.086 1 -1.356
2020-06-30 0.299 1 -0.061

PSTV Price Target

For more insight on analysts targets of PSTV, see our PSTV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.88 Average Broker Recommendation 1.5 (Moderate Buy)

PLUS THERAPEUTICS, Inc. (PSTV) Company Bio


PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.


PSTV Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTV Latest Social Stream


Loading social stream, please wait...

View Full PSTV Social Stream

Latest PSTV News From Around the Web

Below are the latest news stories about PLUS THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTV as an investment opportunity.

Plus Updates Financial and Cash Guidance for 2024

Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance

Yahoo | December 18, 2023

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

Collaboration to explore novel CSF cancer testing modalities and initial testing panel to be available in Q1 2024 for ReSPECT-LM patientsAUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has partnered with K2bio (Houston, Texas) to implement novel analysis for cere

Yahoo | December 12, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany. 5th Annual Radiopharmaceutic

Yahoo | November 29, 2023

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 months, compared to SOC at 4 months Rhenium (186Re) Obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by external

Yahoo | November 20, 2023

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here.

Yahoo | November 15, 2023

Read More 'PSTV' Stories Here

PSTV Price Returns

1-mo -6.22%
3-mo 3.42%
6-mo 35.07%
1-year -56.59%
3-year -94.93%
5-year -99.07%
YTD 3.42%
2023 -63.19%
2022 -69.81%
2021 -48.02%
2020 -15.83%
2019 -83.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!